AstraZeneca’s Gout Drug Lesinurad Hobbled By Renal Risk
This article was originally published in The Pink Sheet Daily
Lower dose of oral, uric acid transporter inhibitor shows good efficacy in two of three Phase III trials, but renal safety risk appears to limit lesinurad’s potential market – if it gets approved at all.
You may also be interested in...
Zurampic, which AstraZeneca licensed to Ironwood, pushed the limits of FDA's tolerance of the regulatory compromises agency has had to make in gout; our Drug Review Profile shows how statistician's case against approval received serious consideration, although the agency ultimately valued consistency with previous approvals in the space.
FDA is concerned about product's narrow therapeutic index, but advisory committee says it’s not an issue for approval; could this be addressed in post-marketing trial?
Company already offering boxed warning and post-marketing cardiovascular study as advisory committee meeting nears.